What’s new for psoriatic arthritis Find out next. Apremilast Otezla. new hope for psoriatic arthritis The American College of Rheumatology puts out hotlines on new drugs. Here’s the one on apremilast. Apremilast is the first oral agent approved by the FDA for the treatment of PsA. While its efficacy profile is modest compared to biologic therapy, it has a favorable safety profile and the convenience of oral dosing. It may be most appropriate for patients with less severe joint and skin manifestations who may not yet require a biologic DMARD. There are also emerging data in patients with psoriasis only suggesting apremilast is moderately.